Cancer remains the second leading cause of death in the world, and numbers are on the rise. To respond to the growing need for therapeutic solutions, much research is needed. In this episode of The Onco’Zine Brief Peter Hofland, Ph.D. talks with Susan Pandya, MD.

Pandya is Vice President Clinical Development and Global Head of Cancer Metabolism at Servier Pharmaceuticals. She is also a board-certified Hematologist-Oncologist and a master clinician with a passion for innovation in cancer treatment. In her current role as Vice President of Clinical Development at Servier Pharmaceuticals Pandya is overseeing hematology and oncology clinical development programs. She is involved in developing novel therapeutics in rare oncology indications and is leading teams with the design, planning, and execution of Phase 1 and Phase 3 global pivotal studies.

Hofland and Pandya talk about how Servier Pharmaceuticals has made oncology one of the company's foremost priorities and endeavors to become a major player in treatments for cancers that are difficult to treat and for which therapeutic needs are generally not yet met, such as gastrointestinal, hematologic, pancreatic and pediatric cancers.

About The Onco'Zine Brief
The Onco'Zine Brief is distributed in the United States via PRX (Public Radio Exchange). In the United Kingdom and Europe, the program is distributed via UK Health Radio (UKHR). And the program can be downloaded via most podcasts and streaming media services, including iTunes, Spotify, TuneIn, and iHeart Radio.

For more information about The Onco'Zine Brief or how to sponsor or support this public radio broadcast and podcast, visit: http://www.oncozine.com to download our Media Kit or visit Patreon at https://www.patreon.com/theoncozinebrief to support the program.

For more information about cancer and cancer treatments, visit our online journal Onco'Zine at www.oncozine.com

To sign up for The Onco'Zine Newsletter (open for residents of the United States only), text the word CANCER to 66866.